Cepheid
Kerry J Flom is an accomplished executive with extensive experience in clinical affairs and regulatory submissions, currently serving as Executive Vice President and Chief Regulatory Officer at Cepheid since 2013. Previously, Kerry held senior roles at Cepheid from 2004 to 2012, focusing on infectious disease, oncology, and genetics MDx clinical trials. Prior to Cepheid, Kerry worked as Senior Director of Clinical Affairs/Submissions at Vysis/Abbott Molecular and held director positions at Baxter Healthcare Inc. and Oncor Inc. Kerry's academic credentials include a Ph.D. in Biochemistry and a Ph.D. in Microbiology from the University of Illinois Urbana-Champaign, where studies were completed between 1975 and 1981.
This person is not in any teams
Cepheid
9 followers
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.